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ABSTRACT Chemokines and cytokines are critical for initiating
and coordinating the organized and sequential recruitment and
activation of cells into Mycobacterium tuberculosis-infected
lungs. Correct mononuclear cellular recruitment and localization
are essential to ensure control of bacterial growth without the
development of diﬀuse and damaging granulocytic inﬂammation.
An important block to our understanding of TB pathogenesis lies
in dissecting the critical aspects of the cytokine/chemokine
interplay in light of the conditional role these molecules play
throughout infection and disease development. Much of the
data highlighted in this review appears at ﬁrst glance to be
contradictory, but it is the balance between the cytokines and
chemokines that is critical, and the “goldilocks” (not too much
and not too little) phenomenon is paramount in any discussion
of the role of these molecules in TB. Determination of how
the key chemokines/cytokines and their receptors are balanced
and how the loss of that balance can promote disease is vital to
understanding TB pathogenesis and to identifying novel therapies
for eﬀective eradication of this disease.
INTRODUCTION
Cytokines are soluble, small proteins that are produced
by cells and act in a largely paracrine manner to in-
ﬂuence the activity of other cells. Currently, the term
“cytokine” describes proteins such as the tumor necro-
sis factor family, the interleukins, and the chemokines.
Virtually every nucleated cell can produce and respond
to cytokines, placing these molecules at the center of
most of the body’s homeostatic mechanisms (1). Much
of our knowledge of the function of cytokines has been
derived from studies wherein homeostasis has been dis-
rupted by infection and the absence of speciﬁc cyto-
kines results in a failure to control the disease process. In
this context, infection withMycobacterium tuberculosis
has proven to be very informative and has highlighted
the role of cytokines in controlling infection without
promoting uncontrolled and damaging inﬂammatory
responses (2–4). Herein, we focus on the key cytokine
and chemokines that have been studied in the context
of human TB using experimental medicine as well as
M. tuberculosis infection of various animal models, in-
cluding non-human primates (NHPs), mice, and rabbits.
Perhaps the most important message of this review is
that in a complex disease such as TB the role of any one
cytokine cannot be designated either “good” or “bad”
but rather that cytokines can elicit both protective and
pathologic consequences depending on context.
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Why is TB such an informative probe allowing for
detailed investigation of the function of cytokines and
chemokines in immunity? One recent development in
our understanding of TB stems from theories of coevo-
lution between modern humans andM. tuberculosis (5).
Evolutionary patterns based on genetic analyses suggest
that M. tuberculosis and humans coexisted for tens of
thousands of years in Africa but that, when humans
left Africa and developed a more urban lifestyle, TB
developed into a substantial health problem (6). During
coevolution between humans and M. tuberculosis,
M. tuberculosis likely evolved tools and stratagems
with which to manipulate the human immune response
to ensure effective transmission (7); this manipulation
has been so successful that it is thought that over one-
third of the world’s population harbors some form of
M. tuberculosis infection (8).
Two facts illustrate the focus of M. tuberculosis
on manipulating the human immune response. First,
M. tuberculosis is the major active constituent of com-
plete Freund’s adjuvant, which has been used for de-
cades to stimulate long-lived cellular immune responses
in vertebrate animals. Second, we have exploited the
strong and sensitive T-cell-based inﬂammatory response
to M. tuberculosis antigens as a skin test to indicate in-
fection withM. tuberculosis. Thus, teleologically speak-
ing, we may suggest that M. tuberculosis does not fail
to induce immunity, it simply manipulates it such that
its need to be transmitted is met. This manipulation
occurs from the start of the human M. tuberculosis in-
teraction when immune surveillance cells of the lung
recognize danger through binding of their pattern rec-
ognition receptors to exquisitely reﬁnedM. tuberculosis
pathogen-associated molecular molecules. It is this ini-
tial interaction that results in production of chemokines
and cytokines, which then recruit and activate inﬂam-
matory cells (9). Following this initial interaction, bac-
teria migrate to the draining lymph node where they
initiate (quite effectively) antigen-speciﬁc T cells that dif-
ferentiate into cytokine-producing cells capable of ex-
pressing a variety of chemokine receptors that allow them
to trafﬁc away from the lymph node and into sites of
tissue inﬂammation (7, 9). These antigen-speciﬁc T cells
must then migrate via chemokine gradients, colocate with
M. tuberculosis-infected phagocytic cells, and release cy-
tokines that activate the infected cells to kill theM. tuber-
culosis (7, 9). If this induction of immunity is not met
by M. tuberculosis, then the host dies rapidly with no
effective transmission of the bacterium to further hosts.
The need for communication between cells both for
efﬁcient migration and for speciﬁc instruction during
expression of immunity is where the critical role of
cytokines and chemokines in controlling TB lies. Indeed,
for the majority of those infected with M. tuberculosis,
the efﬁcient expression of immunity via competent cy-
tokine and chemokine expression results in no sign of
disease other than an ability to exhibit an inﬂammatory
response to M. tuberculosis antigen (i.e., the skin test
response). However, forM. tuberculosis to be efﬁciently
transmitted, a degraded inﬂammatory lesion capable of
delivering live bacteria to the airways must develop, and
it is this evolutionary need that likely drives the devel-
opment of the disease process in the lung. M. tubercu-
losis expresses molecules that promote inﬂammatory
responses, which then need to be regulated to avoid
tissue damage. If the bacterial burden is large or if the
bacteria proliferate rapidly, then the coordination be-
tween cells mediated by cytokines and chemokines can-
not occur quickly enough and immunity cannot be
expressed, despite the presence of all of the required
components. Understanding the functions and interac-
tions between cytokines and chemokines is therefore
critical to our attempts to limit TB. Herein, we discuss
the roles of speciﬁc cytokines (Table 1) and chemokines
(Table 2) in the context ofM. tuberculosis infection and
how they function to stop the development of TB, and
also how they might contribute to the progression of
disease.
CYTOKINES
Tumor Necrosis Factor Alpha
Tumor necrosis factor alpha (TNFα) is a cytokine that
is released following activation of the immune system.
Although it is primarily produced by macrophages,
TNFα can also be secreted by lymphocytes, mast cells,
endothelial cells, and ﬁbroblasts (10). Because most
cells exhibit responsiveness to TNFα, it is considered a
major proinﬂammatory mediator. It is produced as a
type II transmembrane homotrimeric protein (mTNF)
that can become released into the extracellular milieu
through the proteolytic action of TNFα-converting
enzyme (TACE) (11). Soluble TNF (sTNF) exists as a
51-kDa trimeric protein that is unstable on reaching
nanomolar concentrations (12), but which on binding
to cognate TNF receptors (TNF-R) induces activation
of proinﬂammatory responses mediated by NFκB, JNK,
and p38, as well as promotion of apoptosis (10, 13–16).
There are two TNF receptors, TNF-R1 and TNF-R2.
Both TNF-R1, also known as CD120a and p55/60,
and TNF-R2, also known as CD120b and p75/80, can
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bind either the membrane or the soluble form of TNFα
(17–19). An important regulator of activation is locali-
zation of receptor expression, as TNF-R1 is ubiquitously
expressed, whereas TNF-R2 expression is restricted to
subsets of neuronal cells, T cells, endothelial cells, mi-
croglia, oligodendrocytes, cardiac myocytes, thymocytes,
and human mesenchymal stem cells (20). Signaling
through TNF-R2 can only be activated through mTNF,
and not sTNF. This complex interplay between positive
and negative regulators of TNF activity reﬂects the po-
tential disruptive power of TNFα, and this regulation of
immunity provides tempting targets for manipulation by
M. tuberculosis.
Originally described for its ability to promote necrosis
of tumors (21), TNFα has since been implicated in pro-
liferation and differentiation of immune cells, as well as
multiple inﬂammatory processes including migration (20)
and apoptosis of M. tuberculosis-infected cells in vitro
(22, 23). Upon initial M. tuberculosis infection, the in-
teraction between immune surveillance cells such as
phagocytes in the lung and the invadingM. tuberculosis
results in the production of multiple proinﬂammatory
cytokines, including TNFα (4) (Fig. 1). Although both
virulent and avirulentM. tuberculosis are able to induce
comparable levels of TNFα by human alveolar macro-
phages, TNFα produced in response to infection with
virulentM. tuberculosis strains has less bioactivity (24).
This is an example of the ability of the bacterium to
manipulate the host response, because the decreased
TNFα bioactivity has been attributed to the induction
of IL-10 by the virulent strain, which then results in
release of soluble TNF-R2 that binds the induced TNFα,
thereby inhibiting its function (24). As infection prog-
resses, TNFα plays a role in coordinating the chemokine
response within the lung and in facilitating the devel-
opment of the granuloma; it is also produced by both
CD4 and CD8 T cells and plays an important role in
optimal macrophage activation (25).
In M. tuberculosis infection models, the importance
of TNFα is exempliﬁed by mice deﬁcient in the TNF
receptor or following TNF neutralization (26). In these
models, TNFα deﬁciency results in increased suscep-
TABLE 1 The positive and negative roles of cytokines in TB
Cytokine Receptor/signal Role in TB
TNFα TNFR1, TNFR2
JNK, p38, NFκB
Positive: Essential for survival following M. tuberculosis infection. Initiation of innate cytokine and
chemokine response and phagocyte activation.
Negative: Mediator of tissue damage.
IFNγ IFNGR1, IFNGR2
JAK/STAT
Positive: Essential for survival following M. tuberculosis infection. Coordinates and maintains
mononuclear inﬂammation. Expressed by antigen-speciﬁc T cells.
Negative: Potentially pathogenic.
IFNα/IFNβ IFNAR1, IFNAR2
JAK, TYK, ISG, ISRE
Positive: Required for initial recruitment of phagocytes to the lung.
Negative: Overexpression of IFNα/IFNβ results in recruitment of permissive phagocytes and regulation
of T-cell accumulation and function.
IL-6 IL-6R, gp130
JAK, STAT3, MAPK
Positive: Potentiates early immunity – nonessential unless a high-dose infection.
IL-1α/IL-1β IL-1R1, IL1RAcP
MyD88, IRAK4, NFκB
Positive: Essential for survival following M. tuberculosis infection. Induction of IL-17. Promotes PGE2
to limit type I IFN.
IL-18 IL-18Rα, IL-18Rβ
MyD88, IRAK, NFκB
Positive: May augment IFNγ – nonessential. Regulator of neutrophil and monocyte accumulation,





Positive: IL-12p40 and IL-12p35 essential for survival following M. tuberculosis infection. Mediate early
T-cell activation, polarization, and survival.





Positive: Required for IL-17 and IL-22 expression during M. tuberculosis infection. Nonessential in
low-dose challenge required for long-term control.





Positive: May control inﬂammation and reduce pathology.
Negative: Regulates protective immunity to M. tuberculosis infection by limiting the migration and





Positive: Regulate the availability of subunits of IL-12, IL-27.
Negative: Potential immunoregulatory role.
IL-17A/F IL-17RC, IL-17RA Positive: Essential for survival following infection with some strains of M. tuberculosis. Induction and
maintenance of chemokine gradients for T-cell migration.
Negative: Drives pathology via S100A8/A9 and neutrophils.
IL-22 IL-22R1, IL-10R2
TYK2, JAK1, STAT3
Positive: Induces antimicrobial peptides and promotes epithelial repair, inhibits intracellular growth of
M. tuberculosis in macrophages.
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tibility with mice succumbing to infection within 2 to
3 weeks, while harboring a high bacterial burden (26).
Critically, although inﬂammatory cells accumulate at
the site of M. tuberculosis infection in TNFα-deﬁcient
mice, they do not coalesce to form granulomas (26–29).
Granulomas are considered to be a hallmark of TB and
are composed of macrophages, multinucleated giants
cells, CD4+ and CD8+ T cells, B cells, and neutrophils
(30). In one of the earliest studies of the role of TNFα in
mycobacterial disease, it was shown that TNFα neu-
tralization following BCG infection led to the loss of
granulomas (31). Neutralization of TNFα also leads to
decreased expression of key chemokines such as CCL5,
CXCL9, and CXCL10. CXCL9 and CXCL10 both bind
to the receptor CXCR3 (32, 33), expressed on activated
T cells, while CCR1 and CCR5, expressed on both in-
nate (i.e., macrophages and neutrophils) and adap-
tive cells (i.e., T and B cells), bind to CCL5 (34). Thus,
TNFα sits at the crossroads where innate immunity and
acquired immunity, as well as cytokines and chemo-
kines interact. In the absence of TNFα, T cells express-
ing CXCR3 fail to encounter the ligands CXCL9 and
CXCL10 required to recruit these cells into the granu-
loma. Thus, the required communication between in-
fected phagocytes and the instructive T cells does not
occur, resulting in loss of immunity.
The importance of the granuloma in restricting the
movement ofM. tuberculosis to more immunoprivileged
sites has long been appreciated (35). Indeed, inhibition
of TNFα promotes dissemination of M. tuberculosis to
sites such as the central nervous system (CNS) (36, 37)
wherein adverse events are profound and often irre-
versible. It is thought that M. tuberculosis migrates to
the CNS secondarily from a primary site elsewhere in the
host (38, 39), although how it crosses the blood-brain
barrier is not clear. Although TNFα is produced in the
CNS and is thought to exacerbate progression of TB-
related damage in the CNS in a rabbit model (40), use
of neuron-speciﬁc TNFα-deﬁcient mice has shown that
neuron-derived TNFα production is dispensable for
protection against CNS-TB (41). These data support
the notion that TNFα is critical for the initiation and
coordination of cellular responses, but that it has the
potential to be pathogenic when expressed in the ab-
sence of immunity.
TNFα is required throughout the life of the infected
host because reactivation of pulmonary TB occurs in
latently infected mice upon neutralization of TNFα (42).
Upon neutralization, less deﬁned granuloma formation
is seen along with increased bacterial burden in the lung
and extrapulmonary sites such as the liver and spleen
(42) (Fig. 2). Enhanced histopathology is also observed
in TNFα-neutralized mice, supporting the importance
of a regulated cellular interaction duringM. tuberculosis
infection. The protective role of TNFα is further high-
lighted in those patients with autoimmune and chronic
diseases who are undergoing anti-TNFα-neutralizing
therapies, including inﬂiximab, adalimumab, and etan-
ercept (43, 44). Although this therapy is successful at
treating the autoimmune disease, a signiﬁcant correla-
tion between reactivation of latent TB in patients un-
dergoing anti-TNFα therapy has been reported (45–52).
Patients using inﬂiximab and/or adalimumab have a
higher incidence of TB reactivation in extrapulmonary
sites compared with etanercept (50). While a mechanism
for this has not been determined, mathematical model-
ing and bioinformatic analysis suggest that reactiva-
tion is related to drug tissue penetration, drug half-life,
TABLE 2 The positive and negative roles of chemokines in TB
Chemokine Receptor Role in TB
CCL-3,-4,-5 CCR1 Positive: Upregulated during infection. Nonessential in mouse model
CCL-2,-7,-12 CCR2 Positive: Maximizes and organizes early macrophage and T-cell accumulation in the lung
Negative: Mediates recruitment of permissive phagocyte accumulation into the lung
CCL-17,-22 CCR4 Positive: Mediates optimal granuloma formation to mycobacterial antigen
Negative: May limit T-cell proliferation via TREG
CCL-3,-4,-5 CCR5 Positive: Regulation of pulmonary inﬁltrates – nonessential. May mediate early dendritic cell
accumulation in the lymph node. May augment macrophage M. tuberculosis killing via CCL5?
CCL-20 CCR6 Positive: Expression of CCR6 on T cells speciﬁc for M. tuberculosis antigens
Negative: CCL-20 seen at high levels in active TB
CCL-19,-21, CCR7 Positive: Mediates eﬃcient migration of dendritic cells and M. tuberculosis-speciﬁc T-cell activation.
CXCL-1,-2,-3,-5,-6,-7,-8 CXCR1
CXCR2
Positive: Expressed on neutrophils mediates accumulation
Negative: Absence of CXCR2 or CXCL5 results in improved bacterial control and reduced neutrophil
accumulation
CXCL-9, -10,-11 CXCR3 Positive: Required for optimal granuloma formation. Expressed on M. tuberculosis-speciﬁc T cells.
Use of CXCL9-11 levels to indicate disease level? Required for early recruitment of T cells to lung
CXCL-13 CXCR5 Positive: Required for correct location of T cells within granulomas. Required for B-cell follicle
formation in M. tuberculosis-infected lungs. Required for optimal protection.
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and relative speciﬁcity for membrane-bound TNFα or
soluble TNFα (53). An intriguing mechanism for the ef-
fect of inﬂiximab on immunity to M. tuberculosis in-
fection has been suggested by the observation that this
antibody-based drug binds to mTNF expressed on effec-
tor memory CD8 T cells, thereby facilitating complement-
mediated lysis and likely loss of M. tuberculosis-speciﬁc
CD8 T cells (54). In a cynomolgus macaque model of TB,
latently infected primates were given either soluble TNFα
or adalimumab and exhibited increased reactivation
FIGURE 1 The role of chemokines and cytokines in the innate response toM. tuberculosis
infection. Upon early infection of the lower airways, M. tuberculosis encounters alveolar
macrophages and lung epithelial cells. Alveolar macrophages are a major source of pro-
inﬂammatory cytokines (TNFα), although stromal cells can produce cytokines and
chemokines that will also modulate immune responses. During early infection, dendritic
cell traﬃcking from the lungs to the lymph node via CCR7 results in primed naive T cells
and initiation of adaptive immune responses. Replicating bacteria generate a fulmi-
nant reaction that results in the mobilization and recruitment of both neutrophils and
monocytes from the bone marrow via the induction of proinﬂammatory cytokines and
chemokines. Regulation of cellular recruitment occurs via coordinated cytokine and
chemokine induction. While initial recruitment of monocytes requires type I IFN, over-
expression of this cytokine results in high levels of CCR2-expressing monocytes with
limited ability to control bacterial growth. Type II IFN (IFNγ) regulates the recruitment of
neutrophils, which is promoted by IL-17. CXCL5 and CXCR2 mediate the recruitment of
damaging neutrophils. Mtb, M. tuberculosis.
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and harbored higher bacterial burdens than their latently
infected untreated counterparts (55). As would be ex-
pected because of the higher bacterial burden and the role
of TNFα in limiting bacterial spread, there were more
granulomas in the lungs of the treated monkey (26, 55).
In the zebraﬁsh model of Mycobacterium marinum in-
fection, TNFα is required for control of mycobacterial
growth and to regulate macrophage necrosis (56).
The ability to rapidly diagnose active disease from
latent infection would be highly beneﬁcial in identiﬁca-
tion and prompt treatment of TB. TNFα has recently
been proposed as a biomarker to distinguish between
active pulmonary disease and latently infected individ-
uals who do not exhibit disease symptoms (57). Using
polychromatic ﬂow cytometric analysis, patients with
pulmonary TB disease have a higher proportion of single
positive TNFα-producingM. tuberculosis-speciﬁc CD4+
T cells compared with individuals with latent infection
(57). This was further conﬁrmed in a blinded study
whereby this parameter was the sole diagnostic for
pulmonary TB disease (57). TNFα lies at the crux of the
TB conundrum. It is critical for control of infection with
both phagocyte-activating and granuloma-organizing
functions, but too much TNFα can mediate tissue dam-
age and promote transmission (Table 1).
The Interferons
The interferon family demonstrates the potential for
similar cytokines to play protective and pathologic roles
in TB disease. Based on receptor speciﬁcity and sequence
homology, the interferons (IFNs) are classiﬁed into two
types (58). IFNγ is the only type II interferon and, while
structurally related to the type I interferons IFNα and
IFNβ, these cytokines use different receptors and have
FIGURE 2 The role of chemokines and cytokines in the adaptive response to M. tuber-
culosis infection. Following M. tuberculosis infection of the lung, migratory cells take
the bacteria to the draining lymph node likely using both cytokine (IL-12p40) and
chemokine (CCR2, CCR7) pathways. Antigen is then transferred to antigen-presenting
cells that stimulate naïve T cells via MHC class I and class II. Antigen-presenting cells make
cytokines and chemokines to potentiate T-cell proliferation and polarization. Activated
T cells migrate from the draining lymph node through the vasculature to the inﬂamed
site. Some T cells remain in the vasculature (CX3CR3+) while others migrate into the
parenchyma (CXCR3+CCR6+). Expression of CXCR5 on antigen-speciﬁc T cells allows
them to respond to IL-23- and IL-17-dependent CXCL13 and locate eﬀectively within
the granuloma, where they activate M. tuberculosis-infected macrophages. T cells ex-
press a variety of cytokines in the lung including IFNγ, TNFα, IL-17, and IL-10 that have
both protective and negative eﬀects depending upon the context.
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distinct chromosomal locations (58). Unlike type I IFNs
that bind to a common heterodimeric receptor com-
posed of IFNAR1 and IFNAR2 chains, IFNγ binds to the
IFNγ receptor (IFNGR) which comprises two ligand-
binding IFNGR1 chains that associate with two signal-
transducing IFNGR2 chains (58). In addition, while
IFNγ is essential for survival following M. tuberculosis
infection the type I IFNs appear to be largely detrimental
to the host during TB and may be coopted by the bac-
terium for its own ends (Table 1).
Type II interferon (IFNγ)
IFNγ-IFNGR binding induces signaling within the cell
primarily through the Janus kinase/signal transducers
and activators of transcription (JAK-STAT) pathways
and results in changes in both the migratory and func-
tional capacity of multiple cell types such as macro-
phages, NK cells, and T cells (59–61). Innate production
of IFNγ by phagocytes stimulated through their pattern
recognition receptors results in early proinﬂammatory
responses to infection (58, 62) and, unlike TNFα, which
is regulated tightly by highly related molecules, pro-
duction of IFNγ is regulated by cytokines such as IL-12
and IL-18, which are also secreted by immune surveil-
lance cells upon ligation of their pattern recognition
receptors (58, 63, 64).
Genetic deﬁciency in the IFNγ pathway in humans
is associated with increased risk for mycobacterial dis-
ease and Mendelian susceptibility to mycobacterial dis-
ease (MSMD) (65, 66). Autosomal complete recessive
IFNγR1-deﬁcient patients exhibit a predisposition for
mycobacterial infections manifesting early in life and
with poor prognosis (67). IFNγR2 deﬁciency (either
total protein loss or loss of function) has also been ob-
served and results in a similar outcome to IFNγR1 de-
ﬁciency (68, 69). Similarly, mice that do not express
IFNγ because of targeted gene disruption are severely
susceptible to both low-dose aerosol (70) and intrave-
nous infection (71, 72) and exhibit poor macrophage
activation and exacerbated granulocytic inﬂammation
(70, 71).
The classic function of IFNγ is as a phagocyte-
activating cytokine which instructs macrophages and
other cells to change function. In particular, in the ab-
sence of IFNγ M. tuberculosis occupies an intracellular
environment wherein there is little reactive radical pro-
duction; the phagosome does not fuse with lysosomes
and remains at neutral pH. There is also an ample supply
of iron due to the location of the phagosome in the early
endosomal pathway (73). While innate sources of IFNγ
can activate macrophages, there is very little control of
M. tuberculosis growth in the absence of α/β T cells or
major histocompatibility complex (MHC) class II fol-
lowing aerosol infection (74), suggesting that both IFNγ
and antigen-speciﬁc T cells are required for control of
this infection. However, whether it is T cells producing
IFNγ that are critical has not been deﬁnitively demon-
strated, but the strongest support of a critical need of
CD4+ T cells to make IFNγ is from a transfer model in
mice (75). In contrast, memory T cells can mediate pro-
tection in the absence of either IFNγ or TNFα, suggesting
other functions need to be identiﬁed (76). Both CD4+
and CD8+ T cells produce IFNγ and accumulate within
the infected lung and, while absence of CD4+ T cells re-
sults in rapid susceptibility to M. tuberculosis infection,
the absence of CD8+ T cells results in susceptibility later
in the infection (77). The organization of the granuloma
is also disrupted in the absence of CD4+ T cells with
predominantly perivascular cufﬁng of lymphocytes ob-
served (78), suggesting that, in the absence of CD4+ T
cells, chemokine gradients are not established for T-cell
migration. It is also the case that, while CD8+ T cells
can make IFNγ during M. tuberculosis infection, they
require CD4+ T cells to do so optimally (79).
The induction of IFNγ-producing T cells has been the
focus of anti-TB vaccine design but has not been par-
ticularly fruitful. It is clear that humans need antigen-
speciﬁc T-cell responses to control TB (because those
with human immunodeﬁciency virus [HIV]/AIDS de-
velop TB readily) and that absence of IFNγ promotes
mycobacterial disease in humans, so why have we not
progressed? Again, we come back to the issue of the
communication between the T cells and the infected
phagocytes. If the T cells are unable to colocate with the
phagocytes and/or the phagocytes are unable to respond
to the signals delivered by the T cells, then the number of
IFNγ-producing T cells circulating throughout the body
is meaningless. It is therefore the case that IFNγ pro-
duction by activated T cells is not a correlate of pro-
tection, rather the ability of antigen-speciﬁc T cells to
penetrate and survive within the infected site may be.
In this regard, recent studies demonstrate that not all
cytokine-producing antigen-speciﬁc T cells are able to
penetrate the TB granuloma and some remain in the
vasculature or cuff around the vessels and this is related
to their expression of transcription factors, chemokine
receptors, and differentiation state (80–82); these
markers should perhaps be considered as correlates of
protection.
IFNγ can act on cells other than macrophages; indeed,
its most critical function in TB may not be to activate
macrophages but rather to limit polymorphonuclear
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(PMN) inﬂammation (Fig. 1). Most susceptible mouse
strains exhibit high PMN inﬁltration in the lungs once
infected (83–86), and inhibition of this inﬁltration im-
proves survival (83). Mice that lack IFNγ exhibit high
PMN inﬁltration as do mice lacking CD4+ T cells (70,
78). Neutrophils that lack the IFNγR fail to undergo
apoptosis and accumulate in the lungs ofM. tuberculosis-
infected mice, and their removal improves survival with-
out altering bacterial burden (87). Similarly, chimeric
mice lacking IFNγR on their radio-resistant cells over-
express IL-17 and have excessive neutrophil recruitment
and reduced survival (88). It is possible that the high
IFNγ-producing CD4+ T cells that populate the vascu-
lature (80, 82) are located in such a position to reduce
neutrophil accumulation.
Production of IFNγ is a very useful diagnostic tool
that has been developed to be more selective than the
older skin test assay. In this prominent test for M. tu-
berculosis exposure, M. tuberculosis antigens (selected
to be unique for M. tuberculosis versus other myco-
bacteria) are used to stimulate IFNγ release (89–91).
While this test selects for those who are exposed, it is
not optimized to distinguish between those individuals
who are infected but healthy and those in the process of
developing active disease. Recently, studies have shown
that patients that have more IFNγ-producing T cells are
actually more likely to progress to active disease, sug-
gesting that this test may be optimized to identify those
progressing toward disease (92).
Type I interferon (IFN)
The interferons were ﬁrst identiﬁed more than half a
century ago for their antiviral activity (93). Type I IFNs
represent the largest group, with at least 13 gene prod-
ucts identiﬁed in humans and mice, with IFNα and IFNβ
being the best classiﬁed and the focus of this section. For
clarity, IFNα and IFNβ will be collectively referred to as
IFNα/β throughout this section. The innate response to
pathogens occurs via Toll-like receptor (TLR) engage-
ment resulting in a complex cytosolic cascade of signal
transduction toward IFN-regulatory factor3/7 (IRF3/7)-
mediated transcription of IFNα/β genes (94). Secreted
IFNα/β engages IFN subunit receptors 1 and 2 (IFNAR1/
2) at the cell surface, which then activate dimers of the
tyrosine kinases JAK and tyrosine kinase (TYK) (94,
95). The end result is activation of IFN-stimulated gene
factor (ISG) that then interacts with IFN-stimulated re-
sponse elements (ISRE) at the promoters of IFNα/β-
regulated genes (94, 95).
The type I IFNs were not thought to play a major
role in M. tuberculosis infection and indeed infection
of IFNAR-deﬁcient mice with a low-dose aerosol of
M. tuberculosis Erdman strain did not indicate any
major impact of the loss of this receptor (96). However,
use of strains with increased virulence, such as the
W-Beijing strain HN878, has revealed an important
strain-dependent outcome in relation to type I IFNs. The
pathogenesis of M. tuberculosis strain HN878 is asso-
ciated with IFNα/β-dependent reduction in the activity
of the proinﬂammatory cytokines IFNγ, TNFα, IL-6,
and IL-12, as well as in the anti-inﬂammatory IL-10
(97, 98) (Fig. 1). Intranasal delivery of IFNα/β also
results in increased bacterial burden and reduced sur-
vival in contrast to IFNγ-treated mice (97). Further-
more, IFNα/β signaling interferes with IFNγ-mediated
killing of M. tuberculosis (99). One hypothesis regard-
ing the role of type I IFNs during chronic M. tuberculo-
sis infection is that the accumulation of plasmacytoid
dendritic cells in the lung provides a source of ex-
cess type I IFN which then inhibits the accumulation
of CD4+ and CD8+ T cells in the lung (98) (Fig. 1).
Finally, transcriptional analysis of peripheral blood
cells from those exposed to TB shows that both IFNγ
and type I IFN signatures occur, but that the type I IFN
signature is predominantly associated with neutrophils
(100).
In a mechanistic analysis of the function of IFNα/β in
TB, polyinosinic-polycytidylic acid and poly-L-lysine
and carboxymethylcellulose (poly-IC) were used to in-
duce elevated levels of IFNα/β during M. tuberculosis
infection (101). This poly-IC treatment results in elevated
bacterial burden and increases the recruitment of an
apparently permissive CD11b+GR1int cell phenotype re-
cruited via chemokine (C-C motif) ligand 2 (CCL2) and
C-C chemokine receptor type 2 (CCR2) (101) (Fig. 1).
Similarly, careful analysis of the cells recruited to the
lungs of mice lacking either type I or type II IFN receptors
demonstrates a protective function for type I IFN sig-
naling in that, in its absence, initial recruitment of target
host cells for M. tuberculosis does not occur and immu-
nity is compromised (102).
IFNα/β is another perfect example of a “goldilocks”
cytokine in TB (Table 1). Just enough is required to
initiate recruitment of phagocytes that provide activ-
atable host cells for M. tuberculosis to invade; how-
ever, production of too much IFNα/β results in large
numbers of permissive cells that cannot be effectively
activated. Also, too much of this cytokine can limit the
activation state of the infected phagocytes and poten-
tially limit the accumulation and function of the T cells
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Interleukin-6
Interleukin-6 (IL-6) is a pleiotropic cytokine produced in
response to inﬂammatory stimuli (103) and is involved
in the essential cellular processes of differentiation, pro-
liferation, and apoptosis. Many cell types express IL-6,
including those of lymphoid and nonlymphoid origin
(103), and expression can be induced by other cytokines
including IL-1, TNFα, and IFNγ (104, 105). IL-6 sig-
nals through soluble and membrane-bound IL-6R of
which the glycoprotein 130 dimer (gp130) is an essential
component (106). Downstream signaling is mediated
by a phosphorylation cascade involving JAK, mitogen-
activated protein kinase (MAPK), and STAT path-
ways (106, 107). The pluripotency of IL-6 warrants
regulation and this is mediated by suppressor of cytokine
signaling (SOCS), which inhibits STAT signaling (106,
107).
The relative importance of IL-6 during TB depends
upon the route and dose of infection. As we have dis-
cussed, communication between cells is critical for suc-
cessful expression of immunity and, if the dose is low or
bacteria are slow to grow, then the kinetics of the cel-
lular response are not critical. However, if the dose is
high and systemic, then the kinetics of the response
becomes critical. This concept is illustrated by IL-6, be-
cause in its absence (either by antibody treatment or by
gene deletion) there is increased susceptibility to intra-
venous challenge with a large dose of mycobacteria
(108, 109). In contrast, in a low-dose aerosol M. tu-
berculosis challenge model, while modestly increased
bacterial burden occurs in the lungs of IL-6-deﬁcient
mice, the impact is not lethal (110). In both the low- and
high-dose challenge models, increased IL-4, as well as
reduced or delayed T-cell accumulation and IFNγ ex-
pression, is observed, suggesting that IL-6 can act to
potentiate IFNγ expression at the site of infection (108,
110). It appears also that IL-6 is required for optimal
induction of protective responses during vaccination,
because, in its absence, both BCG and a subunit vaccine
are less effective (109, 111).
Interpretation of the role of IL-6 in TB is complicated
by the fact that the soluble IL-6 receptor can mediate
trans-signaling and is implicated in inﬂammatory dis-
eases such as inﬂammatory bowel disease (112). To
address the role of IL-6 further, a gp130 construct
capable of sequestering IL-6 in the blood (sgp130FC)
was delivered to mice during M. tuberculosis infec-
tion, but no impact on disease progression was seen.
In contrast, when mice are made to overexpress this
construct, a temporary but signiﬁcant increase in bac-
terial burden occurs during acute infection (113).
This observation is consistent with an early role of IL-6
in potentiating immunity during early M. tuberculosis
infection.
In vivo data support a protective role for IL-6 in
the induction of early protective responses mediated
through IFNγ (108, 110). Human studies also give us
considerable insights into the role of IL-6 during TB.
Cavitary TB is the most destructive form of caseous TB
whereby necrosis liqueﬁes cellular material and results
in compromised lung function. Humans with cavitary
TB express lower levels of IL-6 and the chemokine IP-10
in their bronchial alveolar lavage (BAL) ﬂuid in com-
parison with TB patients without cavitary disease,
thereby indicating IL-6 and IP-10 as potential markers
of controlled (noncavitary) TB (114). As would be ex-
pected, elevated neutrophils were observed in BAL from
cavitary TB patients, while noncavitary TB patients
presented with elevated alveolar macrophages (114);
interestingly, there was no correlation between cytokine
expression in BAL ﬂuid and serum cytokine production
(114). In contrast, an earlier study identiﬁed elevated
blood plasma levels of IL-6 from TB patients with de-
veloped lung lesions (115). Based on the mechanistic
data from animal studies and the human data, IL-6
appears to be associated with effective early expres-
sion of immunity in the lung via the combination of
regulated mononuclear inﬂammation and rapid accu-
mulation of lymphocytes. Its effects are modest but may
be critical following high-dose exposure or during im-
munodeﬁciency.
IL-1 Cytokines
The proinﬂammatory cytokines IL-1α, IL-1β (collec-
tively called IL-1 here), and IL-18 are members of
the IL-1 family (116). IL-1 was ﬁrst identiﬁed in the
1940s as an endogenous pyrogen (117–119). IL-1 and
IL-18 as well as their respective receptors (IL-1R1 and
IL-18R) are widely expressed by all nucleated cells
of the body including endothelial cells, monocytes,
macrophages, and neutrophils (116). Expression of IL-1
and IL-18 is mediated in part by the canonical path-
way of inﬂammasome activation, which involves the
sensor (e.g., TLR), an adaptor molecule such as mye-
loid differentiation primary response gene 88 (MyD88),
and caspase-1 (120–122). Alternatively, IL-1β and IL-18
can also be induced by the noncanonical inﬂamma-
some pathway that is distinguished by the activation of
caspase-8 and -11 on the precursor of the cytokines in
the cytosol (123, 124). MyD88 is an important cytosolic
mediator linking TLR signaling to the transcription of
inﬂammasome components (122).
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IL-1α is mostly associated with sterile cell injury (e.g.,
cigarette smoke), but is also induced during nonsterile
cell injury (e.g., bacterial) where it functions locally as
an alarmin (125–130). IL-1β is induced during infection
and is primarily produced by monocytes, macrophages,
and dendritic cells (131–134). IL-1 signals through the
IL-1R1 receptor present on a number of cells including
endothelial cells, monocytes, macrophages, and T lym-
phocytes (116, 128, 135, 136). IL-18 is expressed con-
stitutively in the cytosol at low levels as a precursor,
which is activated by caspase-1 activity following bac-
terial stimulation, stimulation by neutrophils or by IL-4
or IFNγ (137–139). IL-18 activity results from colo-
calization of IL-18 receptor alpha (IL-18Rα) and IL-18
receptor beta (IL-18Rβ) on host cells including mono-
cytes and epithelial cells (140).
IL-1R/IL18R/MyD88
Signaling through MyD88 is shared between TLR,
IL-1R, and IL-18R (141–143). MyD88 is an essential
component in innate signaling in response to TB, be-
cause MyD88 gene-deﬁcient mice exhibit profound
susceptibility to M. tuberculosis infection (143). Impor-
tantly, following mycobacterial stimulation, MyD88
gene-deﬁcient macrophages and dendritic cells exhibit
reduced IL-6, TNF, and IL-12p40 production, suggest-
ing a critical role for MyD88 in pattern recognition
responses to M. tuberculosis infection (143). Aerosol
infection results in dramatically increased lung burden
coinciding with increased inﬂammation and accumula-
tion of neutrophils and macrophages (143). Despite the
poor innate response to M. tuberculosis infection in the
MyD88 gene-deﬁcient mice, the accumulation of IFNγ-
producing T cells was not affected. It is likely that these
antigen-speciﬁc cytokine-producing T cells were unable
to mediate protection because of failures within the
phagocytes accumulating at the site or as a result of
being unable to communicate with the infected phago-
cytes (143). That BCG vaccination results in protection
against M. tuberculosis infection in MyD88-deﬁcient
mice suggests that it is a failure of T cells to accumulate
rapidly enough in naive mice that contributes to their
susceptibility (143).
What then is MyD88 signaling doing? Comparison
of the phenotype of IL-1-deﬁcient mice and MyD88-
deﬁcient mice is suggestive in this regard, because both
exhibit increased susceptibility with focal necrosis de-
spite generation and accumulation of cytokine-producing
T cells (144). These observations suggest that induction
of IL-1 is likely Myd88 dependent and that this pathway
plays a critical role in protective immunity to TB.
IL-1
IL-1α and IL-1β are interdependent proinﬂammatory
cytokines critical to defense against TB (145–149). Mice
lacking either IL-1α or IL-1β or both are susceptible
to acute and chronic infection, respectively, follow-
ing challenge with M. tuberculosis (145–148). IL-1 α/β
double-deﬁcient mice share a similar susceptibility to
infection as IL-1R1KO and MyD88KO mice (143, 144,
148, 150). Deﬁciencies in the IL-1 pathway (IL-1 α/β or
IL-1R1) have no impact on the protection against BCG
delivered intravenously, suggesting that virulence of
the pathogen is a factor in the role of the IL-1 pathway
(146). Anti-IL1α and anti-IL-1α/β antibodies delivered
subcutaneously to M. tuberculosis-infected mice have
also been shown to result in loss of body weight and
lethality (148). Furthermore, lung sections from anti-IL-
1α-treated mice exhibit lung parenchyma consumed
by cellular inﬁltrates (148). During sterile mediated in-
ﬂammation, IL-1α appears to be involved in the ex-
pression of proinﬂammatory cytokines such as IL-6 in
primary ﬁbroblasts (151), which may be associated with
mobilization of neutrophils (152). It has also recently
been observed that, upon activation of the inﬂamma-
some, IL-1β and IL-18 are capable of inducing expres-
sion of the neutrophil-recruiting cytokine IL-17 (153–
155). IL-17 responses are essential in the protection
against some M. tuberculosis strains, such as HN878
and for recall responses to H37Rv (149, 156, 157).
Consistent with this, IL-1R1 gene-deﬁcient mice infected
with the M. tuberculosis strain HN878 produce de-
creased levels of IL-17 and decreased populations of
IL-17-producing cells in vitro and in vivo (149).
IL-1 is produced by CD11b+Ly6G– cells following
M. tuberculosis infection (145), and rescue of the lethal
phenotype in IL-1α mice can be accomplished by di-
rected viral expression of IL-1α in CD11c+ cells trans-
planted in IL-1α gene-deﬁcient mice (147). It would
seem, therefore, that a primary function of the IL-1/
IL-1R pathway is to mediate the recruitment and coor-
dination of cellular responses by the induction of pro-
inﬂammatory cytokines from the stroma (145, 147).
One critical aspect of IL-1 function is in promotion of
prostaglandin E2 (PGE2), which in turn mediates inhi-
bition of type I IFN-induced accumulation of permis-
sive macrophages at the site of infection (158) (Fig. 1).
Prostaglandins such as PGE2 are produced by the action
of cyclooxygenase (COX) enzymes on arachidonic acid,
and, in the absence of inducible COX enzymes, mice are
highly susceptible to M. tuberculosis infection, and de-
livery of PGE2 during M. tuberculosis infection results
in a partial rescue of the lethal phenotype in IL-1α/β-
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infected mice (158). Taken together, the underlying
function of IL-1 in M. tuberculosis appears to be in
regulating type I IFN function and helping to maintain
the balance between sufﬁcient phagocytes to mediate
control of the intracellular pathogen, while inhibiting
the overrecruitment of permissive macrophages medi-
ated by type I IFN (102).
IL-18
IL-18 is essential for the production of IFNγ from T cells
under some conditions (159–163), and, in some in-
stances, its absence can result in increased susceptibility
to M. tuberculosis (150), although, in other conditions,
increased susceptibility to M. tuberculosis infection is
not observed (162, 163). Interestingly, when suscepti-
bility is observed, the accumulation of neutrophils and
inﬂammatory chemokines CXCL1 and CXCL2 is ele-
vated, and depletion of neutrophils and monocytes from
the lung results in decreased bacterial burden (150).
In M. tuberculosis-infected IL-18-deﬁcient mice, an in-
creased frequency of IFNγ-producing CD4+ and CD8+
T cells in the lungs is seen, but total IFNγ production
by these T-cell populations is decreased, suggesting that
IL-18 could contribute to optimal IFNγ induction during
TB (150, 162, 163). It would appear, therefore, that
IL-18 plays a role in inducing high IFNγ production in
T cells, but that this is not required for protection, and
that its more critical role (perhaps when dose or viru-
lence of theM. tuberculosis strain is high) is that of reg-
ulator of phagocyte accumulation, possibly mirroring
the role of IL-1 and MyD88.
Our working model of immunity to TB places the
emphasis on rapid and correct accumulation of both
phagocytes (macrophages and neutrophils) and T cells
to the site of infection. This accumulation is initiated
by the innate sensors within the lung and results in the
induction of TNF, IFNs, and IL-1 family members. The
correct ratio of these cytokines is essential for the bal-
ance of permissive and nonpermissive phagocytes and
for the development of a granuloma such that infected
phagocytes and antigen-speciﬁc T cells can communi-
cate effectively to stop M. tuberculosis growth. How
the antigen-speciﬁc T cells develop and are regulated is
covered below.
IL-12 Cytokine Family
The IL-12 family of cytokines belongs to the IL-6 su-
perfamily and is the only family composed of hetero-
dimeric cytokines (164, 165), and this unique feature
bestows diverse and pleiotropic functions because of
promiscuous chain pairing (166). The alpha chains of
the IL-12 family (p19, p28, and p35) contain four-helix
bundle structures and pair with one of two beta chains
(either p40 or Epstein-Barr virus-induced gene 3 [Ebi3])
(164–166). IL-12 is composed of the subunits p35/p40,
IL-23 of p19/p40, IL-27 of p28/Ebi3, and IL-35 of p35/
Ebi3 with expression of the distinct subunits being reg-
ulated independently (166). In addition, IL-12p40 can
also be secreted both as a homodimer (IL-12p80 or
IL-12p(40)2) and as a monomer (IL-12p40) (167). Both
macrophages and dendritic cells are major producers of
IL-12p40, IL-12, IL-23, and IL-27 (168). These cyto-
kines are largely associated with the induction and reg-
ulation of cytokine expression within antigen-stimulated
T-cell populations.
IL-12
IL-12 plays an important role as a link between innate
and adaptive immune responses, and is produced by and
inﬂuences multiple effector cells (169, 170). Composed
of IL-12p35 and IL-12/23p40, IL-12 (IL-12p70) is pri-
marily secreted by macrophages, dendritic cells, and
B cells (166, 171, 172). The importance of IL-12 in TB
is dramatically illustrated by several experiments of na-
ture wherein humans with IL-12p40 deﬁciency display
an inherent predisposition to M. tuberculosis infection
(173–178). Furthermore, patients with MSMD harbor
deﬁciencies in IL-12Rβ1, IFNγR1, and IL-12p40, and
exhibit susceptibility to M. tuberculosis and develop
BCGosis following delivery of the BCG vaccine (66,
178–181). Genetic etiology forMSMD is associated with
mutations in the autosomal genes IFNGR1, IFNGR2,
STAT1, IL12B, IL12BR1, and X-linked gene IKKBG,
encoding NF-κB essential modulator (NEMO) (66). All
these autosomal genes are associated with IL-12/IFNγ-
dependent signaling and the IFNγ-mediated activation
of macrophages. Mutations in IKKBG impair CD40-
dependent IL-12 production in monocytes and dendritic
cells, despite normal CD40-mediated induction of co-
stimulatory molecules on dendritic cells (182). These
human data highlight the importance of this pathway to
TB control.
IL-12 is expressed within the lung at the site of TB
(183) and delivery of IL-12 to M. tuberculosis-infected
mice decreases bacterial burden, while reduction of
IL-12 by antibody increases bacterial burden (184). In-
terestingly, delivery of IL-12 also modestly improves
the outcome for mice lacking acquired cellular immu-
nity, suggesting that it can mediate immunity via direct
action on innate cells (184). Mice genetically deﬁcient
for the IL-12p40 subunit are acutely susceptible to
M. tuberculosis infection (185, 186), whereas those
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lacking IL-12p35 exhibit prolonged survival relative
to the IL-12p40-deﬁcient mice (186). This, in turn, is
dependent on the availability of the IL-23p19 subunit
(187). The absence of IL-12p40 results in the substantial
loss of antigen-speciﬁc IFNγ production (185, 186)
(Fig. 2), while the presence of IL-23p19 in the IL-12p35-
deﬁcient mice appears to promote sufﬁcient antigen-
speciﬁc IFNγ production to increase protection relative
to the IL-12p40-deﬁcient mice (187). It also appears
that stable and prolonged IL-12 production is required
to maintain IFNγ production and to limit bacterial
growth long term (188). This requirement for long-term
function may also apply in humans, because absence
of the IL-12R1 results in poor accumulation of IFNγ-
producing memory T cells (189). The innate pattern
recognition receptors, TLR2 and TLR9, are necessary
for optimal production of IL-12p40 in response to M.
tuberculosis exposure (190), while the M. tuberculosis
lipoarabinomannans have been shown to negatively
regulate TLR-mediated IL-12 production by inducing an
inhibitor of TLR signaling, IRAK-M (191). In contrast,
mycobacterial LprA is a TLR2 agonist and promotes IL-
12p40 production (192), reﬂecting the need for M. tu-
berculosis to both induce and regulate IL-12p40 for its
own ends.
IL-12 signals through interactions between IL-12/
23p40, and IL-12p35 with IL-12Rβ1 and IL-12Rβ2,
respectively (193–195), with the IL-12p40 interacting
with IL-12Rβ1 on the target cell surface, thereby allow-
ing the IL-12Rβ2 to induce JAK and STAT signaling
and activate STAT4 homodimers (166). The homodimer
IL-12p40, IL-12(p40)2, antagonizes IL-12-mediated im-
mune responses through competitive binding of IL-
12Rβ1 (196–198). However, in TB, it appears that IL-12
(p40)2 can also function as an agonist (199), and sup-
ports dendritic cell migration to the draining lymph
nodes (200, 201), to promote T-cell priming and dif-
ferentiation (200). Speciﬁcally, following M. tuberculo-
sis infection, dendritic cells are thought to be the ﬁrst
immune cells to trafﬁc to the draining lymph node (202),
and this may occur in an IL-12p40- and IL-12Rβ1-
dependent manner (200, 203). Bone marrow-derived
dendritic cells from mice deﬁcient in IL-12p40 are un-
able to activate naive T cells in the draining lymph node
following delivery to the lung and fail to confer protec-
tive adaptive responses (200). However, treatment of
the IL-12p40-deﬁcient dendritic cells with the homo-
dimer IL-12(p40)2 is sufﬁcient to restore migration of
the dendritic cells to the draining lymph node and for
activation of naive T cells to occur (200). Expression
of IL-12Rβ1 is also required to facilitate dendritic cell
migration to the draining lymph node (203) and, indeed,
CD11c+ cells in theM. tuberculosis-infected lung express
an alternative splice variant of IL-12Rβ1 that augments
IL-12Rβ1-mediated effects (203). In particular, dendritic
cells expressing the splice variant exhibit enhanced mi-
gration from the infected lung to the draining lymph
nodes and supported activation of M. tuberculosis-
speciﬁc T cells (203) (Fig. 2). In an interesting example of
cytokine cross talk, mice lacking the p75 receptor for
TNF (TNFRp75) exhibit increased IL-12p40 and en-
hanced IL-12p40-mediated dendritic cell trafﬁcking
to draining lymph nodes (204). Thus, IL-12Rβ1 is im-
portant for the effector function of IL-12p40 on den-
dritic cells, as well as mediating recruitment and function
of CD4 T cells in response to TB.
IL-23
IL-23 utilizes the p40 beta subunit paired with the alpha
chain p19 (205). Before the discovery of IL-23, the
interpretation of data from IL-12p40- and IL-12p35-
deﬁcient models of disease had been difﬁcult (206).
Speciﬁcally, studies found that the outcome of IL-12p35
deﬁciency was not always the same as in IL-12p40-
deﬁcient models (207–209). The discovery of IL-23 led
to the reassessment of the role of IL-12p40 (205, 206,
208, 209), and disease models previously associated
with IL-12 were, in fact, shown to be primarily driven by
IL-23 and not IL-12 or they clariﬁed unique disease-
driving features of the two cytokines (206, 208–211).
Currently, IL-23 and IL-23 pathway antagonists are in
phase 2 and phase 3 clinical trials for treating patients
with moderate to severe psoriasis (207), making the
determination of the role of IL-23 in TB a critical un-
dertaking. IL-23 stabilizes the induction of the TH17
cell subset, which produces IL-17A, IL-17F, and IL-22,
and it is also required for the double expression of IL-17
and IFNγ (212). However, IL-23 alone is not sufﬁcient
to drive differentiation of TH17 cells, which requires
the key cytokines transforming growth factor β (TGFβ)
and IL-6 (213). In addition, IL-23 can also induce IFNγ
production in human T cells as well as support the
proliferation of mouse memory T cells (205, 214). The
interaction with its receptor, composed of IL-23R and
IL-12Rβ1 subunits, activates the downstream signaling
molecules, JAK and STAT, for production of its signa-
ture cytokines (166, 205, 214–216). IL-23 primarily
signals through STAT3, while IL-12 can signal through
STAT1, 3, 5, and 4, but preferentially signals through
STAT4 (166). Upon infection withM. tuberculosis, lung
dendritic cells produce IL-23, likely mediating the in-
duction of IL-17 production (187, 217, 218).
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Although IL-23 is important for generation of M.
tuberculosis-speciﬁc IL-17-producing T cells (Fig. 2),
mice deﬁcient in IL-23p19 control M. tuberculosis ef-
fectively for up to 90 days whereupon bacterial growth
increases relative to intact mice (187, 219). In addi-
tion, treatment of M. tuberculosis-infected mice with
adenovirus-expressing IL-23 reduces M. tuberculosis
burden and increases cellular responses (220). In the
absence of IL-23p19, M. tuberculosis-infected mice did
not develop well-organized B-cell follicles, and this was
associated with a complete absence of IL-17 and IL-22
in the lung. In addition, there was very little expression
of the B-cell follicle-associated chemokine CXCL13
resulting in increased accumulation of lymphocytes
around the vessels rather than within the granulomatous
regions (219) (Fig. 2). Thus, in support of our working
model, coordinated communication between lympho-
cytes and infected macrophages is inefﬁcient in the
absence of speciﬁc cytokines/chemokines (in this case,
IL-23-dependent CXCL13) and bacterial growth occurs
in the absence of this efﬁcient communication.
IL-23 also plays a chemokine-dependent role in the
efﬁcient expression of vaccine-induced mucosal immu-
nity. This role was ﬁrst highlighted in mice subcutane-
ously vaccinated with an adjuvant-paired I-Ab-restricted
ESAT6(1-20) peptide, which induces both IFNγ- and
IL-17-producing antigen-speciﬁc CD4+ T cell responses
(157). Critically, the improved kinetics of the vaccine-
induced IFNγ-producing T cells is lost in the absence
of IL-23, because this cytokine is required for the gen-
eration of lung resident IL-17 producing CD4+ memory
T cells that generate a chemokine gradient facilitating
the accelerated IFNγ response. In the absence of IL-23,
vaccine-induced protection to M. tuberculosis challenge
is lost (157). Coimmunization of mice with a DNA vac-
cine composed of M. tuberculosis antigen 85B (Ag85B)
and an IL-23-expressing plasmid also confers enhanced
protection through the induction of augmented T-cell
proliferation and IFNγ production in comparison with
Ag85B alone (217). Other studies also support an im-
portant role for IL-17-producing CD4+ T-cell subsets in
mediating mucosal vaccine-driven protection (156, 221–
223). Speciﬁcally, adoptive transfer of M. tuberculosis-
speciﬁc IL-17-producing T cells into unchallenged mice
confers protection following exposure toM. tuberculosis
(156). Furthermore, use of adjuvants capable of driving
lung-resident IL-17-producing cells is able to initiate
early CXCL13 expression, thereby promoting appro-
priate accumulation of CXCR5+ T cells within the
M. tuberculosis-induced inﬂammatory site (221). These
IL-17-producing T cells are long lived (222) and are
associated with improved protection when recombinant
BCG vaccines are used (223).
IL-27
IL-12 and IL-23 are proinﬂammatory cytokines with
the capacity to drive cytokine production in T cells
(168, 224, 225). In contrast to this clear role for IL-12
and IL-23, IL-27 is pluripotent and has a complex and
sometimes apparently contradictory capacity to inﬂu-
ence inﬂammation and lymphocyte function (166, 226–
228), indicating a pleiotropic nature for IL-27. IL-27
is composed of the p28 alpha and Ebi3 beta chains,
and signals through the IL-27Rα (WSX-1 or TCCR)
and gp130 receptor subunits (166, 229, 230). IL-27
can mediate suppression of IL-17-production by T cells
(231) via STAT1 signaling to promote IL-10-producing
Tr1cell-like regulatory populations (232). It also pro-
motes proliferation (229) and polarization via T-bet
(233) in naive T cells (Fig. 2).
In the context of M. tuberculosis infection, IL-27R-
deﬁcient mice challenged with M. tuberculosis exhibit
lower bacterial burden in the lungs and increased gran-
uloma-localized lymphocytes (234, 235), but these mice
succumb to disease earlier than control animals (235).
Thus, while IL-27R activity appears to limit expression
of immunity locally, it may actually protect from undue
pathologic damage. Because of the pleiotropic nature
of IL-27 it is very difﬁcult to dissect out its speciﬁc
function in TB. The absence of the gp130 component
of the IL-27R on phagocytes during M. tuberculosis
infection results in loss of the increased inﬂammatory
consequences of IL-27R deﬁciency but does not impact
the reduced bacterial burden seen in mice lacking IL-27R
on all cells, suggesting that these two aspects of IL-27R
deﬁciency are independent (236). In contrast, mice
lacking IL-27R only on T cells exhibit the improved
ability to control bacterial burden over the long term
(82). This improvement was associated with enhanced
localization and reduced differentiation (i.e., reduced
T-bet expression) of IL-27R-deﬁcient CD4+ T cells
within the infected lung parenchyma. M. tuberculosis-
speciﬁc CD4+ T cells lacking IL-27R are also intrinsi-
cally ﬁtter than IL-27R-sufﬁcient CD4+ T cells in mice
within the same environment (82) (Fig. 2). The impor-
tance of IL-27 is further conﬁrmed in human patients,
wherein IL-27 is signiﬁcantly increased in patients with
active TB compared with latently infected individuals
(82). In our working model of TB immunity, IL-27
appears to play the role of mediator of increased in-
ﬂammation within the phagocyte population while
also serving to limit the efﬁcacy of the T-cell population
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by driving them to a state of differentiation that limits
their ability to locate to, and persist within, the inﬂamed
granuloma.
IL-35
IL-35, a dimeric protein encoded by IL-12α and IL-
27β chains, has been shown to suppress CD4+ T-cell
responses (237). It is thought to be primarily expressed
by regulatory T (TREG) cells (238) and is required for
optimal function both in vivo and in vitro (239). IL-35 is
important for the generation of human and mouse TREG
cells, termed iTR35 cells (239), which function inde-
pendently of IL-10 and TGFβ. While a speciﬁc function
for IL-35 in M. tuberculosis infection has not been di-
rectly addressed, the relative availability of IL-35 in the
presence and absence of the other IL-12 family subunits
makes consideration of this cytokine an important part
of any interpretation of outcome in mice or humans
lacking IL-12 family subunits.
IL-23-Dependent Cytokines
IL-17
The IL-17 cytokine family is composed of six members,
IL-17A to IL-17F, with IL-17A and IL-17F being the
most studied. Production of IL-17 is conventionally at-
tributed to T cells, but other lymphocytes as well as in-
nate immune cells can produce this cytokine (240). IL-17
cytokines are proinﬂammatory and can be protective
or pathogenic depending on the nature of the challenge
faced by the host (241, 242). It is at mucosal sites that
IL-17 plays its most important regulatory and protective
role against invading pathogens.
Following mycobacterial infection, lung-resident γδ
T cells are a primary source of early IL-17 (218), and
likely support early neutrophil accumulation (243)
(Fig. 1). Following BCG infection, IL-17 expression can
be detected as early as day 1 postinfection and is de-
pendent on IL-23 expression (243). One recently iden-
tiﬁed capacity of IL-17 is to regulate mycobacterially
induced IL-10 (244). Following vaccination with BCG,
dendritic cells produce PGE2, which is required for the
induction of both IL-10 and IL-23 with the IL-23 being
required for IL-17 production (244). This IL-17 is then
thought to downregulate IL-10 production, thereby
allowing increased IL-12 that subsequently promotes
IFNγ production. In the absence of IL-10, the IL-23-
mediated IL-17 is not required and, in the absence of
IL-23, BCG fails to effectively induce protective IFNγ-
producing T cells (244). This study was the ﬁrst to show
that PGE2 induction of IL-17 was sufﬁcient to overcome
the inhibitory effects of IL-10 and support the genera-
tion of antigen-speciﬁc and cytokine-producing T cells
during mycobacterial vaccination and challenge.
As with IL-23, low-dose challenge with some strains
of IL-17A (i.e., H37Rv and CDC1551) in the absence of
IL-17 results in no obvious phenotype (149, 187, 245)
until late in disease (219). In contrast, following infec-
tion with the W-Beijing strain HN878 of M. tuberculo-
sis, IL-17R expression on radio-resistant cells (likely
ﬁbroblasts) of the lung is required to coordinate the
rapid accumulation of cells within the lung via the in-
duction of CXCL13 and recruitment of CXCR5+ T cells
to lymphoid follicles within the tissue (149) (Fig. 2).
Importantly, the W-Beijing HN878 M. tuberculosis
strain induces high levels of IL-1β and IL-17 relative to
other M. tuberculosis strains (149) and also induces
excess type I IFN (97), which is capable of bringing in
permissive macrophages in a CCR2-dependent manner
(101) (Fig. 1). HN878 induces an environment that is
highly permissive for its growth, and it is this environ-
ment that results in the need for the optimum expression
of immunity wherein IL-17 promotes rapid accumula-
tion and the correct localization of the T cells needed to
change the permissive macrophages to ones that limit
bacterial growth (149).
The role of IL-17 in initiating early coordination of
cellular responses in naive mice is apparent when the
challenge is signiﬁcant as in the case of HN878; how-
ever, the concept of IL-17 as a coordinator of early
mucosal responses in TB actually stems from vaccine
work. Initial studies using a deﬁned subunit vaccine
determined that lung-resident IL-17-producing cells in-
duced by vaccination are vital for the induction of the
chemokines (CXCL9, CXCL10, and CXCL11) required
for the accumulation of IFNγ-producing memory T cells
(157). Further studies have shown that adoptive transfer
of M. tuberculosis-speciﬁc IL-17-producing T cells into
naive mice is able to mediate protection in an aerosol
challenge model, thereby identifying these types of cells
as valid targets for vaccine-mediated induction (156).
Finally, mucosal immunization with M. tuberculosis
antigens induces potent IL-17 responses that improve
upon BCG vaccine-induced protection in mice (221).
Interestingly, in mucosal vaccine models, IL-17 rather
than IFNγ appears to be most important for vaccine-
induced protection against M. tuberculosis, providing
support for the model that it is the coordination of the
cellular response that is the determining factor in the
success of vaccination (221, 246). Critically, antigen-
speciﬁc IL-17-producing memory T cells are induced by
vaccination and respond up to 2 years postvaccination
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(222). These memory T cells appear to be metastable
and become IFNγ producers within the lung (222),
probably as a result of the action of IL-23 (212). In fact,
pluripotent memory T cells capable of producing not
only IL-17 but also TNF and IL-2 may be the most ap-
propriate target T cells for vaccination (247). Manip-
ulation of BCG can also result in increased induction of
IL-17-producing memory cells, and this is associated
with improved protection as in the case of the recom-
binant BCG strain rBCGΔureC:Hly (223). Thus, IL-17
drives the induction of CXCL9-11 to recruit protective
antigen-speciﬁc T cells, as well as CXCL-13 to localize
CXCR5+ cytokine-producing T cells within TB granu-
lomas. Despite the protective outcome of IL-17 dis-
cussed above, IL-23-dependent IL-17 production is
also associated with damaging neutrophil accumulation
during a chronic restimulation model of TB (248). In-
deed, exacerbated production of IL-17 appears to drive
pathology by inducing S100A8/A9 proteins that recruit
neutrophils into the lung (249). Thus, IL-17 also ﬁts the
bill as a “goldilocks” cytokine in TB (Table 1).
IL-22
IL-22 is primarily produced by CD4+ T cells as well as
γδ T cells, natural killer (NK) cells, and innate lymphoid
cells following exposure to innate or infectious stimuli
(250). IL-22 can have dual effects in the context of in-
ﬂammation, and this has been attributed to its coexpres-
sion along with IL-17 (250, 251). The major functions of
IL-22 are the regeneration and survival of the intestinal,
airway, and external epithelium, as well as stimulating
the secretion of antimicrobial peptides such as lipo-
calin and β-defensin (245, 250, 252). In the context of
M. tuberculosis, IL-22 is expressed at higher levels than
IL-17 at the site of infection and within granulomas from
TB patients and NHP models (253, 254). Furthermore,
in NHPs infected with M. tuberculosis, CD4+ T cells
expressing membrane-bound IL-22 limitM. tuberculosis
intracellular growth in macrophages (255). IL-22 can
also inhibit intracellular growth of M. tuberculosis in
human monocyte-derived macrophages by promoting
phagolysosomal fusion and induction of Calgranulin A,
a heterodimer of S100A8 and S100A9 proteins (256).
Moreover, human NK cells cultured with M. tubercu-
losis-infected macrophages produce IL-22 and mediate
macrophage activation (257). Finally, IL-22 increases as
patients receive anti-TB treatment, and this has been
associated with a decrease in a regulatory B-cell popu-
lation (CD19+CD1d+CD5+ B cell), the in vitro depletion
of which results in enhanced IL-22 production by T cells
(258).
Animal studies using low-dose aerosol challenge in-
dicate that, in uncomplicated infection models, IL-22-
producing T cells accumulate in the lung and express
IFNγ (259). In the absence of this cytokine, however,
there appear to be no signiﬁcant consequences (260).
However, in a BCG vaccine model, NK1.1+ cells appear
to make IL-22, which contributes to protection by reg-
ulating TREG cells (261). Taken together, the current data
suggest a protective role for IL-22 in TB disease pro-
gression, possibly via antimicrobial peptide production,
cellular function, and promotion of epithelial repair.
Regulatory Cytokines
IL-4, IL-5, IL-13
IL-4 was ﬁrst described as a product of CD4+ T lym-
phocytes that are now known as TH2 T cells (262, 263).
TH2 responses inhibit TH1 responses (264–266). IL-4,
IL-5, and IL-13 are the signature cytokines associated
with TH2 responses; they are induced in response to
helminth infections and contribute to diseases such as
asthma and allergy (267–270); they mediate expulsion
of multicellular parasites occupying mucosal tissues.
IL-4R signaling requires heterodimerization of IL-4Rα
(shared with IL-13) and the common gamma chain
(shared with IL-2) (271). The IL-4 receptor (IL-4R) is
the primary mediator of action, and ligation of IL-4R
results in signal transduction via STAT-6 and subse-
quent GATA-3 transcription (272–275). Both STAT-6
and GATA-3 distinguish TH2 cells from other TH cells,
including TH1 and TH17 (270). IL-4 expression is, in
part, regulated by IL-2 and is associated with the dif-
ferentiation of TH2 cells, which then express and main-
tain IL-4 and IL-5 in a positive feedback loop (276, 277).
IL-4R is expressed on many cell types, including lym-
phocytes, epithelial cells, and ﬁbroblasts (278, 279).
IL-5 is primarily associated with recruitment of eosino-
phils (280) and basophils (281) and the development of
antibody-producing B cells (282, 283). The IL-5 receptor
comes in both low- and high-afﬁnity forms whose ac-
tivity is context dependent when expressed on the sur-
face of lymphocytes, eosinophils, and basophils (284).
During TB, IL-4 levels are quite variable, with mRNA
detectable in peripheral blood mononuclear cells (285)
and IL-4-producing T cells isolatable from TB patients
(286); however, peripheral blood mononuclear cells
from active, M. tuberculosis culture-positive patients
show decreased IL-4 expression (287–289). While a
signiﬁcant increase in IL-4 is observed in the plasma
of TB patients compared with household contacts
(290), IL-4 plasma levels are not different between HIV
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patients and non-HIV patients with TB (290, 291), and
anti-TB treatment is associated with decreased plasma
IL-4 levels (290). IL-4 mRNA has been shown to be
upregulated in the necrotic areas in the lungs of HIV+
patients with pleural TB (292) and is consistent with
increased CD4+ cells expressing IL-4 in TB patients ex-
hibiting cavitary disease (293). In an NHP model, IL-4-
expressing T cells are increased transiently at week 6
post-M. tuberculosis infection; however, this population
is not sustained (294). One reason for the variable asso-
ciation of IL-4 expression with disease proﬁle may lie in
the fact that infection with M. tuberculosis is associated
with expression of the IL-4 antagonist IL-4δ2, and it may
be the relative levels of IL-4 and its splice variant that
deﬁne the impact of the cytokine on disease outcome
(295–297).
Aerosol M. tuberculosis infection of mice deﬁcient
in IL-4, IL-4/IL-13, IL-4Rα, or STAT-6 fails to result in
early differences in bacterial burden (298, 299) despite
increased levels of IFNγ (110); however, during chronic
infection, bacterial burden increases in IL-4Rα and
STAT-6 gene-deﬁcient mice (298). IL-4 can inﬂuence
M. tuberculosis-induced granulomas, because overex-
pression of this cytokine by adenovirus results in in-
creased accumulation of monocytes and eosinophils
within the granuloma (300). This demonstrates that IL-4
has the potential to deviate the M. tuberculosis-induced
granuloma from its mononuclear to a more granulocytic
characteristic (35, 301), but that its impact on disease is
not strong.
Information regarding the role of IL-5 in TB is lim-
ited; however, following intranasal infection of IL-4- or
IL-5-deﬁcient mice with BCG effective clearance is ob-
served with no differences in bacterial burden or lung
pathology among IL-4- and IL-5-deﬁcient mice (302).
One area where this cytokine may play a role, however,
is in HIV coinfection, because IL-5 is not observed in
NHP monocytes infected with M. tuberculosis, but,
during coinfection with simian immunodeﬁciency virus
(SIV), IL-5 and IL-13 are increased (303). NHP models
coinfected with SIV andM. tuberculosis show disrupted
CD4+ T-cell levels (303), and the mechanism of loss
appears to be related to monocyte-derived IL-5 that was
induced following SIV infection (303).
IL-13 was originally described as a T-cell-derived
cytokine capable of inhibiting proinﬂammatory cyto-
kine production (304, 305); IL-13 function has since
been extended to include regulating airway restriction
and antihelminth responses (306–308). Furthermore,
IL-13 is not only produced by TH2 cells, but can also be
generated by invariant NK T cells (iNKT), granulocytes
(e.g., basophils, eosinophils, and mast cell), murine
group 2 innate lymphoid cells (ILC2s), and human
“chemoattractant receptor-homologous molecule ex-
pressed on TH2 lymphocytes” (CRTH2)-type 2 ILCs
(309–313). It is structurally similar to IL-4 and signals
through cell surface receptor heterodimers composed of
IL-4Rα and IL-13Rα1 subunits to activate STAT6 (313).
Although not much is known regarding IL-13 in
M. tuberculosis infection, whole blood mRNA from la-
tently infected children shows increased IL-13 compared
with uninfected controls (314), although IL-13 levels
are not different between actively and latently infected
children (314). IL-13 may play a modulatory role in
autophagy, which is an important homeostatic mecha-
nism for intracellular degradation and has a protective
function during mycobacterial infection (315–317). In-
deed, in both murine and human macrophages, IL-13
and IL-4 are independently capable of inhibiting auto-
phagy as well as IFNγ-induced autophagy-mediated
killing of M. tuberculosis (317). Transgenic mice over-
expressing IL-13 succumb to infection with M. tuber-
culosis sooner than control mice and have more necrotic
granulomas within the lung (318), and this is associated
with delayed expression of IFNγ and IL-17-producing
CD4+ T cells and increased arginase production by
macrophages within the necrotic granulomas (318).
While this overexpression of IL-13 represents an artiﬁ-
cial situation, it highlights the potential for disruption
of the T-cell response to have a profound effect on TB
development. Studies utilizing IL-13 gene-deﬁcient mice
are necessary to truly uncover the distinct role for IL-13
in TB.
Transforming Growth Factor β
TGFβ is a pleiotropic cytokine and regulates hundreds
of genes (319–322) to modulate inﬂammation, cell pro-
liferation, and differentiation, as well as cell migration
(323–325). TGFβ can be made by various cell types,
including all leukocytes (e.g., lymphocytes, macro-
phages, monocytes, dendritic cells) (325, 326). Not sur-
prisingly, the impact of TGFβ on disease outcomes is
dependent on cell type and stage of cellular differentia-
tion, as well as the cytokine milieu (327).
TGFβ levels are increased in blood monocytes iso-
lated from TB patients compared with uninfected
individuals (328), and TGFβ localizes primarily to mul-
tinucleated Langhans giant cells within the granulo-
mas of TB patients (328). TGFβ is induced in human
blood monocytes by M. tuberculosis lipoarabinoman-
nans (329), and human monocytes treated with TGFβ
allow for increased intracellular M. tuberculosis sur-
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vival, suggesting that TGFβ can play a regulatory role
and potentially negative role in the context of M. tu-
berculosis infection (330). T cells and monocytes from
TB patients cocultured with natural inhibitors of TGFβ,
such as decorin and latency-associated peptide, exhibit
restored T-cell proliferation and monocytic control of
M. tuberculosis, again suggesting that TGFβ is a regu-
latory inhibitor of both T-cell responses and antibacte-
rial activity (331). TGFβ is also able to induce IL-10 and
to synergize with this cytokine to suppress IFNγ pro-
duction (332). The contribution of TGFβ poly-
morphisms to TB susceptibility is not clear (333, 334).
The polymorphism +869T/C does not correlate with
increased susceptibility in a Chinese population (334),
whereas the same polymorphism in an Indian popula-
tion reveals a signiﬁcant susceptibility toM. tuberculosis
in patients harboring this polymorphism. Our knowl-
edge of the importance of context in the function of
TGFβ suggests that other genetic or indeed cultural
differences may mask the contribution of this polymor-
phism. Taken together, the data suggest that TGFβ plays
an inhibitory role in host responses to M. tuberculosis
infection.
IL-10
IL-10 was initially identiﬁed as a “cytokine synthesis
inhibitory factor” produced by Th2 cells (335). How-
ever, IL-10 can be produced by other T-cell subsets
including TH1 and TH17 cells, macrophages, some den-
dritic cell subsets, myeloid-derived suppressor cells,
B cells, and neutrophils (336). In addition, TREG cells are
also a major source of IL-10 and serve to limit poten-
tially pathogenic immune responses (336). IL-10 signals
through the IL-10R, which comprises IL-10R1 and
IL-10R2 (337). IL-10R1 is induced on hematopoietic
cells, while IL-10R2 is expressed constitutively on most
tissues and immune cells (336). In myeloid cells, IL-10
production can occur via TLR-MyD88-dependent path-
ways (338), as well as TLR-independent C-type lectin
receptor engagement (339).
In the context of TB, meta-analyses suggest that
polymorphisms in the IL-10 gene, speciﬁcally −1082G/A
polymorphisms in Europeans and −592A/C polymor-
phisms in Asians, are signiﬁcantly associated with TB
risk (340). Furthermore, antigen-speciﬁc IL-10 produc-
tion is found in pulmonary TB patients (341, 342) and,
along with TNFα production, can be used to reliably
distinguish between latent TB and pulmonary TB (342).
In addition, increased accumulation of TREG cells ex-
pressing IL-10 correlates with increased bacterial burden
and more severe TB in an Indian population (343, 344),
and a high level of IL-10 at the end of treatment in
pulmonary TB patients is associated with TB recurrence
(345). Finally, infection with helminths in TB patients
results in decreased antigen-speciﬁc IFNγ and IL-17
responses, which are dependent on IL-10, because IL-10
blockade signiﬁcantly increases frequencies of IFNγ-
producing cells (346, 347).
Following mycobacterial stimulation, dendritic cells
and macrophages both produce IL-10 (338, 348). In
macrophages, IL-10 can block phagosome maturation
and macrophage activation in a STAT3-dependent
manner, thus allowing a niche for M. tuberculosis to
replicate and survive within the phagosome (349). In
addition, IL-10 can inhibit aspects of IFNγ-mediated
macrophage activation (350). In dendritic cells, myco-
bacterially induced IL-10 production can inhibit antigen
presentation through the downregulation of MHC class
II molecules, decreased IL-12 production, and inhibition
of dendritic cell trafﬁcking to the lymph nodes for T-cell
priming (351, 352). In keeping with this regulatory role
for IL-10, studies have shown that IL-10 gene-deﬁcient
mice infected withM. tuberculosis exhibit increased TH1
and TH17 responses, and this coincides with improved
M. tuberculosis control during chronic infection (336)
(Fig. 2). The effect is not dramatic and indeed some
challenge models fail to show an impact of IL-10 gene
deﬁciency (299, 353, 354). Interestingly, CBA mice
generate signiﬁcant early macrophage IL-10 production
correlating with increased susceptibility to M. tubercu-
losis infection (355). This increased susceptibility also
coincides with reduced expression of TNFα and IFNγ in
T cells and can be reversed by blocking IL-10R signaling
very early in infection (355). In CBA IL-10 gene-deﬁcient
mice,M. tuberculosis infection results in development of
ﬁbrotic granulomas with similarity to lesions seen in
humans (356). In vaccine models, blocking IL-10 at the
time of BCG vaccination (336), or using IL-10 gene-
deﬁcient mice in BCG vaccination and M. tuberculosis
challenge experiments (244), demonstrates that IL-10
limits IFNγ and IL-17 responses during priming and
decreases vaccine-induced protection against M. tuber-
culosis challenge. Computational modeling also high-
lights the pleiotropic role for IL-10 (357). Importantly,
there are differences in the role of speciﬁc cytokines
depending on the nature of the M. tuberculosis strains
being examined. Indeed, the W-Beijing HN878 strain
induces robust IL-10 production to inhibit the induction
of a Th1 response (98). In the future, therefore, ad-
dressing the role for IL-10 in the context of infection,
a variety of M. tuberculosis strains will likely provide
novel insights into the function of IL-10 in TB.
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THE CHEMOKINES
Limiting bacterial spread and containment of inﬂam-
mation within discrete sites are hallmarks of disease
control in TB and dovetail with the establishment of
the TB granuloma. The TB granuloma is a multicellu-
lar immune bolus consisting of a number of cell types
including macrophages, neutrophils, lymphocytes, and
B cells, among others (358). Formation of the TB gran-
uloma is governed by coordinated expression of the
chemotactic cytokines referred to as chemokines. Che-
mokine expression establishes a chemical gradient that
drives mobilization and recruitment of cells from pe-
ripheral organs to the site of infection and within the
granuloma. The importance of this coordination has
recently emerged to be critical in disease control with
proper localization of CD4 T cells in the lung paren-
chyma being paramount (80–82).
Since the discovery of the ﬁrst chemokine, now
known as CXCL8 (i.e., IL-8), numerous chemokines
have been identiﬁed, resulting in the need for a uniform
nomenclature currently based on primary sequences of
chemokine ligands (359–361). These chemokine ligands
modulate biological processes through interactions with
seven transmembrane G protein-coupled receptors (360,
362). Chemokines are divided into four families (C, CC,
CXC, CX3C) based on the presence of cysteine(s) and
the presence or absence of nonconserved amino acids
between those cysteines (360, 361). The CC chemokine
receptors (CCR) are involved in the recruitment of
monocytes, neutrophils, lymphocytes, and macrophages
(34). During bacterial infection, signaling via pattern
recognition receptors drives the expression of CC che-
mokine ligands (CCL) and the development of gradients
that are responded to by speciﬁc cell surface chemokine
receptors (34) with functional recruitment involving
monomeric or dimeric forms in the respective chemokine
ligands (363). CXC chemokine ligands, denoted as
CXCL, contain a nonconserved amino acid between the
two cysteines, unlike CCL chemokines (360, 361). The
number of chemokine ligands outnumbers the chemo-
kine receptors, suggesting redundant or highly reﬁned
roles for the receptors as in the case for CCR4 expression
mediating the migration of both TH1 and TH2 responses
(363). This is further exempliﬁed by CXC receptors
(CXCR), which are capable of binding multiple CXCLs
to promote the migration of speciﬁc cells along a che-
mokine gradient (360). Because development of the
granuloma and communication between the cells within
the granuloma are so critical for control of disease, this
section will explore the roles chemokines play in mod-
ulating TB disease outcome. In accordance with the most
recent chemokine nomenclature, CCRs and CCLs as
well as CXCRs and their ligands, CXCLs, are numbered
(e.g., CCR2, CCL2) in a manner that avoids the previous
random naming system (364) (Table 2).
CC Receptors and Their Ligands
CCR1
CCR1 is expressed by T lymphocytes, neutrophils, den-
dritic cells, monocytes, and macrophages (365–369).
Under normal conditions, CCR1 is constitutively ex-
pressed at low levels, but it is upregulated during stim-
ulation of neutrophils with granulocyte-macrophage
colony-stimulating factor (GM-CSF) and during the
differentiation of monocytes to macrophages (369, 370).
In TB patients, CD4+ T lymphocytes expressing
CCR1 are elevated in the pleural ﬂuid (371), and, in the
blood, increased levels of CCR1+ T lymphocytes, natural
killer (NK) cells, and neutrophils are seen (372). In vitro,
human neutrophils express both CCR1 and produce
CCL3 upon infection with M. tuberculosis (373). In-
fection with M. tuberculosis induces the expression of
the CCR1 ligands CCL3, CCL4, and CCL5 in the lung
(374, 375); however, CCR1 deﬁciency in mice does not
impact control or disease progression following M. tu-
berculosis infection (35). Thus, it is likely that, while
CCR1 correlates with cellular activation during TB, it
does not appear to play a strong role in protection.
CCR2
CCR2 has a similar distribution pattern as CCR1 on
hematopoietic cells (376, 377). Expression of CCR2
on monocytes and its interaction with CCL2 and CCL7
are essential for mobilization of monocytes from the
bone marrow into the circulation and into sites of in-
ﬂammation (378). Increased levels of CCL2 in the serum
of pulmonary TB and TB patients with disseminated
disease have been reported (379) and are associated
with the damaging inﬂux of inﬂammatory cells during
TB pleurisy (371, 372). At a minimum, the presence of
CCR2 and its ligands is a potential indicator of disease
severity in TB patients.
Low-dose aerosol M. tuberculosis infection of mice
elicits increased expression of CCL2, CCL7, and CCL12
in the lung during the acute stages of M. tuberculosis
infection (380). Accordingly, mice deﬁcient in CCR2 or
CCL2 are defective in macrophage and T-lymphocyte
recruitment following M. tuberculosis infection (380–
383) (Fig. 1). Consistent with defects in recruitment
of immune cells, granuloma formation in CCR2 gene-
deﬁcient mice is delayed, and is associated with peri-
vascular cufﬁng and loosely formed granulomas (380).
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Similarly, M. tuberculosis-infected CCL2 gene-deﬁcient
mice also exhibit decreased granulomatous inﬂamma-
tion inM. tuberculosis-infected lungs (382, 383), despite
these innate and adaptive immune defects, CCR2 gene-
deﬁcient mice are not more susceptible to low-dose
M. tuberculosis infection using either the aerosol or in-
travenous route (380). When taken in the context of the
role of the type I IFNs in recruiting just enough (102) but
not too many phagocytes (101), it may be that using a
simple gene deﬁciency model to dissect the role of each
chemokine or chemokine receptor will not be informa-
tive (Fig. 1).
CCR4
CCR4 is expressed on T-cell subsets including TH17,
TH2, and TREG cells that mediate allergic responses and
protection against extracellular pathogens (384–386).
T lymphocytes expressing CCR4 are mobilized via a
chemokine gradient established by dendritic cells in the
context of both allergic and parasite-induced inﬂam-
mation (387–392). In the context of M. tuberculosis
infection, TREG cells are increased in the peripheral
blood of TB patients and inhibit production of IFNγ
by M. tuberculosis-speciﬁc CD4+ T cells (393, 394),
and CCR4 antagonists promote proliferation of T cells
during MVA85A vaccination (395). The ligand for
CCR4, CCL17, but not CCL22 has also been shown to
be elevated in the serum of active TB patients (396).
These data suggest that CCR4-mediated regulation of
T-cell responses to M. tuberculosis antigens may occur
during TB and that antagonism of CCR4 maybe a target
for therapeutic use or as an adjuvant during vaccination.
Mechanistic analysis of CCR4 function during myco-
bacterially induced granuloma responses demonstrates
that, despite delivery of mycobacterial and helminth
antigens inducing both CCL17 and CCL22 in mouse
lungs, the absence of CCR4 results in reduced granulo-
ma formation in following mycobacterial but not hel-
minth antigen challenge (397). Further investigation of
the role of CCR4 in the development of immunity and
immunopathology is likely warranted.
CCR5
CCR5 is expressed on monocytes, macrophages, T
lymphocytes, neutrophils, and dendritic cells (34, 376,
377, 398) and responds to CCL3, CCL4, and CCL5
(374, 375). CCR5 is most notable in the study of HIV
infection, where CCR5 facilitates viral entry into T lym-
phocytes and macrophages (398, 399). HIV infection
dramatically compromises immunity to TB, and this
is thought to be largely as a result of compromised
T-cell function; however, blocking CCL5 in cultures
of M. tuberculosis-infected alveolar macrophages from
HIV patients results in enhancedM. tuberculosis growth
(374), suggesting that CCL5 can directly promote bac-
terial killing by M. tuberculosis-infected macrophages.
Interestingly, analysis of single-nucleotide polymor-
phisms inCCL5 has identiﬁed two risk haplotypes, A-C-
T and G-C-C, that are associated with susceptibility to
TB (400). What remains unclear is whether this haplo-
type is associated with increased or decreased CCL5
production.
In the mouse model of M. tuberculosis infection, all
three CCR5 ligands are upregulated in the lungs, with
CCL5 being induced to the highest level (375, 401).
Upon M. tuberculosis infection, CCL5 gene-deﬁcient
mice exhibit transient early impairment in granuloma
formation and delayed T-cell recruitment (401), while
CCR5 deﬁciency results in increased inﬂammation in
the lung (375) (Fig. 1). The observed delayed T-cell re-
cruitment into the lungs of CCL5-deﬁcient mice (401) is
not entirely surprising, because CCR5-CCL5 are im-
portant for dendritic cell trafﬁcking to the lymph nodes,
facilitating T-cell activation and accumulation during
TB (375, 401). The difference between the outcome for
the CCR5- and CCL5-deﬁcient mice in terms of inﬂam-
matory outcome may reﬂect the action of other CCR5
ligands acting in the absence of CCL5. The increased
accumulation of CD4+ and CD8+ T lymphocytes, mye-
loid cells, neutrophils, and macrophages in the lungs
of chronically infected CCR5-deﬁcient mice suggests,
however, that any compensating ligand is not optimal
at limiting pathologic consequences (375). Whether the
models are showing true redundancy in the chemokine or
our failure to appreciate the subtle nature of the func-
tion of each chemokine is still an issue for debate (402).
CCR6
CCR6 has only one known ligand, CCL20 (403), and
is expressed on effector and memory T cells, myeloid
dendritic cells, and B cells. CCR6 is important for the
recruitment of CCR6-expressing cells to mucosal sur-
faces and their localization at sites of inﬂammation in
epithelial tissues (403, 404). While CCR6 plays a vital
role under both homeostatic and inﬂammatory condi-
tions, it has been implicated in pathologic conditions,
particularly in cancer and rheumatoid arthritis models
(405, 406). Although few studies have investigated the
role of CCR6 in M. tuberculosis infections, emerging
data support a protective role for CCR6 (407). Speciﬁ-
cally, memory CD4+ T cells speciﬁc for M. tuberculosis
antigens coexpress CXCR3 and CCR6 and these
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CXCR3+CCR6+ CD4+ T cells are associated with an
IFNγ response (386). Following ex vivo expansion, those
CD4+ T cells that produced IL-17A in response to
M. tuberculosis coexpressed CXCR3 and CCR6 (408).
In a detailed analysis of reactivity to mycobacterial an-
tigens it was found that CXCR3+CCR6+ IFNγ-producing
CD4+ T cells from latently M. tuberculosis-infected in-
dividuals responded to three immunodominant antigenic
islands within the M. tuberculosis genome that were all
associated with bacterial secretion systems (409) (Fig. 2).
The CCR6 ligand, CCL20, appears at high levels in pe-
ripheral blood mononuclear cells, myeloid-derived
macrophages, and bronchoalveolar lavage samples from
TB patients (410, 411) and increased CCL20 mRNA is
seen in murine and NHP lung (412, 413). It is likely
therefore that CCR6mediates the localization of memory
cells to sites of M. tuberculosis-induced inﬂammation.
Mouse studies have identiﬁed a critical role for CCR6 in
the innate immune-mediated control following acute
BCG infection (407). Innate cell types, such as CD1b-
restricted iNKT cells, are impacted by the absence of
CCR6, in that they fail to accumulate effectively in the
lung, and this is associated with poor bacterial control
and increased susceptibility to M. tuberculosis infection
(407). Collectively, the current literature suggests that
there is a correlation between CCR6 expression and
bacterial control; however, mechanistic studies investi-
gating the function of CCR6 in innate immune responses
as well as its role in directing memory T-cell migration
are required.
CCR7
Correct localization of dendritic cells and T and B cells is
critical for the function of secondary lymphoid tissues
(414). CCR7 ligation by CCL19 and CCL21 is vital
for the positioning of T cells and dendritic cells in the
paracortical region of these secondary lymphoid organs
(SLO) (415) (Figs. 1 and 2). CCL19 and CCL21 are
constitutively expressed by SLO stromal cells, while
CCL21, but not CCL19, is expressed on lymphatic
endothelial and high endothelial venules (415–418).
CCR7 has also been implicated in thymic function and
development, as well as homeostatic and inﬂammation-
induced migration of dendritic cells to draining lymph
nodes via the afferent lymphatics. In M. tuberculosis
infections, it is thought to be necessary for dendritic
cells from the lungs to relocate in the SLOs, activate
naive T cells, and elicit recruitment of T cells into the
site of infection for bacterial control. Early migration
of mature dendritic cells to the mediastinal lymph node
is supported by CCR7 (419), and CCR7-deﬁcient mice
exhibit impaired dendritic cell migration to this node
(420) (Fig. 2). Similarly, plt mutant mice, which lack
expression of CCL19 and CCL21-Ser in SLO, also have
poor dendritic cell migration (421), and proliferation
of adoptively transferred M. tuberculosis-speciﬁc CD4+
T cells is delayed in mice deﬁcient of CCR7 (420) and plt
mice (422). Interestingly, the CCR7 chemokine ligand,
CCL19, is present within granulomas containing B-cell
aggregates that resemble lymphoid structures, and in
the absence of CCR7 these B-cell follicles are also ab-
sent (416). While these mice display disorganized B-cell
aggregation, the enhanced lymphocytic inﬁltrations ob-
served in the lungs of CCR7 gene-deﬁcient mice are
sufﬁcient to control M. tuberculosis to levels compara-
ble to CCR7-sufﬁcient mice (416). Similarly to CCR7-
deﬁcient mice, plt mutant mice fail to develop B-cell
follicles and have disorganized granulomas (422). How-
ever, unlike CCR7-deﬁcient mice, plt mutant mice also
have delayed accumulation of IFNγ-producing T cells
and maintain higher bacterial burden (422). Thus, it
seems that CCR7 plays an important role in the proper
migration of dendritic cells to the draining lymph node
for priming and activation of T cells, as well as the mi-
gration of CD4+ T cells into lymphoid follicles following
M. tuberculosis infection.
CXC Receptors and Their Ligands
CXCR1 and CXCR2
CXCR1 and CXCR2 share the binding partners,
CXCL6 and CXCL8, while CXCR2 can exclusively
bind to CXCL1-3, CXCL5, and CXCL7 (423). All these
CXCLs contain the ELR motif, corresponding to a Glu-
Leu-Arg tripeptide motif at the amino terminus region,
adjacent to their CXC sequence. The functional role
of this ELR motif is to confer angiogenic activity to
the ELR-containing chemokine (424) and this motif is
important for ligand-receptor binding interactions on
neutrophils (425, 426). Ligand binding to CXCR1 and
CXCR2 causes degranulation, intracellular calcium mo-
bilization, and phosphorylation of MAPK (427).
Although most notably expressed on neutrophils
in TB patients, both CXCR1 and CXCR2 can also be
expressed on NK cells, T cells, and monocytes (423,
428). Comparison of CXCR1 expression on peripheral
blood from TB patients shows that individuals with
pulmonary TB have increased CXCR1, whereas latent
TB patients have increased CXCR2 in whole blood
(429). Moreover, increased CXCR1 correlates with im-
paired oxidative function in leukocytes, suggesting a
possible regulatory role for CXCR1 on oxidative stress
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(429). CXCR2-deﬁcient mice infected intraperitoneally
with Mycobacterium avium have decreased neutrophil
accumulation and increased bacterial burden (430).
However, following pulmonary infection withM. avium,
no difference in cellular inﬁltrate or bacterial burden is
observed, which highlights the importance of route and
dose on identifying the function of the highly redundant
chemokines.
CXCL8 has been the most studied CXCR1/2 ligand
in the context of TB and this important neutrophil
chemoattractant is expressed by multiple cell types, in-
cluding alveolar epithelial cells, monocytes, macro-
phages, and ﬁbroblasts upon M. tuberculosis infection
in vitro (431–434) (Fig. 1). Following in vivo M. tu-
berculosis infection, pulmonary granulomas containing
ﬁbroblasts are also capable of secreting CXCL8 (431),
and TB sputum samples contain elevated CXCL8 levels
(435). CXCL8 is present at high levels at positive tu-
berculin skin reaction sites and is associated with high
levels of neutrophils at this site (436). Furthermore,
neutrophils isolated from pulmonary TB patients have
increased expression of CXCL8, which is further in-
creased following ex vivo infection with H37Rv but not
the clinical strains, S7 and S10, suggesting strain-speciﬁc
regulation of CXCL8 production in neutrophils (373).
Whether CXCL8 is associated with a protective or
pathologic response remains controversial (437, 438).
Serum CXCL8 levels from pulmonary TB patients fol-
lowing treatment with antibiotics decreased, suggesting
that CXCL8 could be a marker for treatment efﬁcacy
(439). Whether disease improvement is directly corre-
lated to reduced CXCL8 levels or simply a reﬂection of
reduced neutrophil accumulation is unclear (Fig. 1).
CXCL5, which is also a CXCR2 ligand, plays an
important role in host responses againstM. tuberculosis
(440), because both CXCR2 and CXCL5 gene-deﬁcient
mice display lower bacterial burden following M. tu-
berculosis infection, which correlates with reduced neu-
trophil accumulation to the lung (440). In this model,
alveolar epithelial secretion of CXCL5, mediating the
recruitment of neutrophils, is dependent on TLR2 en-
gagement with M. tuberculosis and blocking of neutro-
phil recruitment improves outcome in the lung (440)
(Fig. 1). It appears that CXCR2 plays an important role
in the pathologic granulomatous response during TB,
and this could be an important target for host-directed
therapy.
CXCR3
CXCR3 binds to its chemokine ligand partners, CXCL9,
CXCL10, and CXCL11, also known asMIG, IP-10, and
I-TAC, respectively (428, 441). It is expressed primarily
by activated CD4+ and CD8+ T cells, and is detected on
B cells and innate lymphocytes such as NK cells and
NKT cells (428). CXCR3 expression is associated with
supporting localization of cells to the site of infection
(442, 443). Most notably, CXCR3 expression on effec-
tor T cells plays an important role in the migration of
T cells both in vitro and in vivo (33, 441, 444–446) and
the transcription factor T-bet transactivates CXCR3
on T cells to promote this migration (441) (Fig. 2). It is
characterized as an inﬂammatory chemokine receptor
on T cells and is signiﬁcantly enhanced on T cells from
inﬂamed tissues in human inﬂammatory reactions and
has been implicated in various human and murine dis-
ease models, including idiopathic pulmonary ﬁbrosis
and asthma (441, 443, 447).
In response to M. tuberculosis infection, CXCR3-
expressing T cells are found in the caseous, necrotic
granulomas, and bronchoalveolar lavage in the NHP
model, as well as in the lungs of infected mice (428). The
presence of these cells correlates with elevated expres-
sion of CXCL9, CXCL10, and CXCL11 localized
within granulomas (428), but CXCR3-deﬁcient mice do
not exhibit differences in bacterial burden following
low-dose aerosol infection with M. tuberculosis (448,
449). Despite the absence of a bacterial phenotype,
CXCR3-deﬁcient mice do develop fewer granulomas
of decreased size (448, 449), suggesting that CXCR3 is
important for granuloma formation. The coexpression
of CXCR3 with CCR6 on memory T cells in latently
infected humans supports the importance of this re-
ceptor on the migration and function of human T cells
during TB, but the precise role is not clear (Fig. 2). Hu-
man data support a protective role for CXCR3-binding
chemokines because CXCL9 levels correlate with dis-
ease severity (379, 450), although the role of CXCL10
is unclear. CXCL10 has been proposed as a biomarker
for improvement, because reduction of this chemo-
kine in the serum relative to levels at recruitment is ob-
served following TB treatment, and nonresponders do
not show the same decrease (439, 451). Unfortunately,
CXCL10 levels cannot distinguish between active and
latent TB in children (452).
The mechanistic basis for CXCL10 activity in TB is
not fully deﬁned. In some cases, active TB can result in
destruction of the lung parenchyma, leading to cavities.
In AIDS-associated TB, increased CXCL10 is associated
with noncavitary TB, whereas cavitary TB is associated
with increased GM-CSF (114, 453). CXCL10 is im-
portant for modulating CXCL9 and CCL2, which pro-
mote disease, while CXCL10 is signiﬁcantly increased
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in patients with active pulmonary tuberculosis (100),
and there may be a genetic association between a single-
nucleotide polymorphism within the CXCL-10 pro-
moter (135G/A) and TB susceptibility (454).
Additional studies are needed to conﬁrm whether
CXCR3 and its ligands are protective or harmful to
disease outcome. It is also unclear how CXCL9-11 is in-
duced and whether its induction is a direct result of
M. tuberculosis infection or whether upregulated ex-
pression results from expression of cytokines capable of
inducing CXCL9-11 expression (455–458). Still, animal
models support CXCR3 and expression of its ligands
as important regulators for granuloma formation (449,
459) (Fig. 2).
CXCR5
The B-cell chemoattractant, CXCL13, is the only known
ligand for CXCR5. It is preferentially produced in B-cell
follicles and, through its binding with CXCR5, is im-
portant for the development of lymphoid follicles.
In lymphoid organs, the main source for CXCL13
is the follicular dendritic cell (460). However, IL-17-
producing T cells have also been shown to express
CXCL13 in a Candida albicans infection model as well
as in synovial ﬂuid from patients with rheumatoid
arthritis (461). CXCL13 expression recruits CXCR5-
expressing B cells and coordinates the correct position
of these cells within SLO (462). A similar role has also
been highlighted during M. tuberculosis infections.
M. tuberculosis granulomas contain B cells, follicular
dendritic cells, and high endothelial venules and thus
provide important points of entry for trafﬁcking lym-
phocytes (4, 428). CXCL13 is also elevated in M. tu-
berculosis-infected mice and is important for the
localization of CXCR5+ T cells to the lung parenchyma
as well as the activation of phagocytes and control of
bacterial growth (422, 459) (Fig. 2). With the use of
NHP and mouse models of M. tuberculosis, CXCR5+
T cells have been shown to trafﬁc toward ectopic lym-
phoid follicles (bronchus-associated lymphoid tissues
[iBALT]), adjacent to granulomas where CXCL13 is
localized. In the absence of CXCR5, mice fail to develop
iBALT and are more susceptible M. tuberculosis (459)
with the impaired response being rescued through
the adoptive transfer of CXCR5-sufﬁcient T cells, sug-
gesting that CXCR5 expression on T cells is important
for both protection and the development of B-cell folli-
cles. Furthermore, CXCR5 is required for the main-
tenance of M. tuberculosis-speciﬁc CD4+ T cells during
chronic infection (81). B cells from M. tuberculosis-
infected murine lungs are also able to migrate along a
CXCL13 chemotactic gradient in vitro via their ex-
pression of CXCR5 (463). IL-23- and IL-17R-dependent
induction of CXCL13 within the M. tuberculosis-
infected lungs appears to be important for control of this
infection, and CXCL-13- and CXCR5-deﬁcient mice are
the only chemokine-deﬁcient mice that show increased
susceptibility uponM. tuberculosis infection, suggesting
that this cytokine/chemokine axis is nonredundant in
M. tuberculosis infection (Fig. 2).
CONCLUSION
Chemokines and cytokines are critical for initiating and
coordinating the organized and sequential recruitment
and activation of cells into M. tuberculosis-infected
lungs (Figs. 1 and 2). Correct mononuclear cellular re-
cruitment and localization are essential to ensure control
of bacterial growth without the development of diffuse
and damaging granulocytic inﬂammation. An important
block to our understanding of TB pathogenesis lies in
dissecting the critical aspects of the cytokine/chemokine
interplay in light of the conditional role these molecules
play throughout infection and disease development
(Tables 1 and 2). Much of the data highlighted in this
review appear at ﬁrst glance to be contradictory, but it is
the balance between the cytokines and chemokines that
is critical, and the “goldilocks” (not too much and not
too little) phenomenon is paramount in any discussion
of the role of these molecules in TB. Determination of
how the key chemokines/cytokines and their receptors
are balanced and how the loss of that balance can pro-
mote disease is vital to understanding TB pathogenesis
and to identifying novel therapies for effective eradica-
tion of this disease.
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